Annals of Hematology

, Volume 93, Issue 2, pp 233–242

Autologous stem cell transplantation in mantle cell lymphoma: a report from the SFGM-TC

  • Cyrille Touzeau
  • Christophe Leux
  • Reda Bouabdallah
  • Murielle Roussel
  • Richard Delarue
  • Krimo Bouabdallah
  • Catherine Thieblemont
  • Victoria Cacheux
  • Guillaume Cartron
  • Laetitia Compain
  • Emmanuel Gyan
  • Franck Morschhauser
  • Olivier Casasnovas
  • Marie-Pierre Moles
  • Anne-Sophie Michallet
  • Remy Gressin
  • Gandhi Damaj
  • Christian Rose
  • Anne Sirvent
  • Olivier Hermine
  • Mohamad Mohty
  • Noel Milpied
  • Steven Le Gouill
Original Article

DOI: 10.1007/s00277-013-1860-8

Cite this article as:
Touzeau, C., Leux, C., Bouabdallah, R. et al. Ann Hematol (2014) 93: 233. doi:10.1007/s00277-013-1860-8

Abstract

Autologous stem cell transplantation (ASCT) is considered as an attractive treatment option for young mantle cell lymphoma (MCL) patients. This retrospective SFGM-TC study analyzed the outcome of 500 MCL patients treated with ASCT and investigated parameters that may modify the outcome of patients who proceeded to ASCT upfront (n = 396). For all patients, median age at ASCT was 56 years (range, 26–71). Median follow-up was 34 months. Three-year progression free survival (PFS) and overall survival (OS) were 63.5 % [95 % CI, 58.7–68.6 %] and 79.5 % [95 % CI, 75.3–83.4 %], respectively. Median time from ASCT to relapse was 22 months (range, 0–136 m). For patients transplanted upfront and in multivariate analysis, age (HR = 2 [1.2–3.4], p = .01, and HR = 2.3 [1.2–4.5], p = .01), disease status at time of ASCT (HR = 1.7 [1.1–2.6], p = .01 and HR = 1.8 [1.1–3.1], p = .03), and use of rituximab (HR = 0.5 [0.3–0.8], p = .002 and HR = 0.5 [0.3–0.9], p = .01) were statistically predictive for both PFS and OS. Also, first line treatment including anthracycline and high-dose cytarabine followed by ASCT conditioned with TAM improved PFS. To conclude, this study suggests that ASCT in MCL can provide a high response rate but may not be sufficient to cure MCL even when ASCT is performed upfront, highlighting the need for innovative approaches before ASCT, aiming to increase complete response rate, and after ASCT, to maintain response.

Keywords

Mantle cell lymphoma Autologous stem cell transplantation Prognostic factors 

Copyright information

© Springer-Verlag Berlin Heidelberg 2013

Authors and Affiliations

  • Cyrille Touzeau
    • 1
    • 2
    • 3
  • Christophe Leux
    • 4
  • Reda Bouabdallah
    • 5
  • Murielle Roussel
    • 6
  • Richard Delarue
    • 7
  • Krimo Bouabdallah
    • 8
  • Catherine Thieblemont
    • 9
    • 10
  • Victoria Cacheux
    • 11
  • Guillaume Cartron
    • 12
  • Laetitia Compain
    • 13
  • Emmanuel Gyan
    • 14
    • 15
  • Franck Morschhauser
    • 16
  • Olivier Casasnovas
    • 17
  • Marie-Pierre Moles
    • 18
  • Anne-Sophie Michallet
    • 19
  • Remy Gressin
    • 20
    • 21
  • Gandhi Damaj
    • 22
  • Christian Rose
    • 23
  • Anne Sirvent
    • 24
  • Olivier Hermine
    • 7
  • Mohamad Mohty
    • 25
  • Noel Milpied
    • 8
  • Steven Le Gouill
    • 1
    • 2
    • 3
    • 26
    • 27
  1. 1.Department of HematologyUniversity HospitalNantesFrance
  2. 2.INSERM UMR 892University of NantesNantesFrance
  3. 3.Clinical Investigation UnitUniversity HospitalNantesFrance
  4. 4.Department of Epidemiology and BiostatisticsUniversity HospitalNantesFrance
  5. 5.Institut Paoli CalmetteMarseilleFrance
  6. 6.Department of HematologyUniversity HospitalToulouseFrance
  7. 7.Department of HematologyUniversity Hospital NeckerParisFrance
  8. 8.Department of HematologyUniversity HospitalBordeauxFrance
  9. 9.Department of HematologyUniversity Hospital Saint LouisParisFrance
  10. 10.Inserm U728University of ParisParisFrance
  11. 11.Department of HematologyUniversity HospitalClermont-FerrandFrance
  12. 12.Department of HematologyUniversity HospitalMontpellierFrance
  13. 13.Department of HematologyUniversity Hospital Pitié-SalpêtrièreParisFrance
  14. 14.Department of HematologyUniversity Hospital of ToursToursFrance
  15. 15.CIC INSERM U202, CNRS UMR 7292University of ToursToursFrance
  16. 16.Department of HematologyUniversity Hospital of LilleLilleFrance
  17. 17.Department of HematologyUniversity Hospital of DijonDijonFrance
  18. 18.Department of HematologyUniversity Hospital of AngersAngersFrance
  19. 19.Department of HematologyUniversity HospitalLyonFrance
  20. 20.Department of HematologyUniversity HospitalGrenobleFrance
  21. 21.INSERM, U 823University of GrenobleGrenobleFrance
  22. 22.Department of HematologyUniversity HospitalAmiensFrance
  23. 23.Department of HematologySaint Vincent HospitalLilleFrance
  24. 24.Department of HematologyUniversity HospitalNiceFrance
  25. 25.Department of HematologyUniversity Hospital Saint AntoineParisFrance
  26. 26.Centre d’investigation Clinique en Cancérologie (CI2C)University Hospital of NantesNantesFrance
  27. 27.Service d’Hématologie CliniqueCHU de NantesNantes Cedex 1France

Personalised recommendations